LY 03020
Alternative Names: LY-03020Latest Information Update: 25 Nov 2025
At a glance
- Originator Luye Pharma Group
- Class Antidementias; Antipsychotics; Small molecules
- Mechanism of Action 5-HT2C serotonin receptor agonists; Trace amine-associated receptor 1 agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Alzheimer's disease; Schizophrenia
Most Recent Events
- 20 Aug 2025 Luye Pharma Group initiates a phase I trial for Alzheimer's disease (In volunteers) in China (PO, Controlled-release) (NCT07230652)
- 20 Aug 2025 Luye Pharma Group initiates a phase I trial for Schizophrenia (In volunteers) in China (PO, Controlled-release) (NCT07230652)
- 30 Jul 2025 Luye Pharma Group initiates a phase I trial for Alzheimer's disease (In volunteers) in China (PO, Controlled-release) (NCT07292233)